GC0000307A - Pyrimidone compounds and pharmaceutical composition containing them - Google Patents
Pyrimidone compounds and pharmaceutical composition containing themInfo
- Publication number
- GC0000307A GC0000307A GCP20011661A GC0000307A GC 0000307 A GC0000307 A GC 0000307A GC P20011661 A GCP20011661 A GC P20011661A GC 0000307 A GC0000307 A GC 0000307A
- Authority
- GC
- Cooperation Council for the Arab states of the Gulf
- Prior art keywords
- pharmaceutical composition
- composition containing
- pyrimidone compounds
- pyrimidone
- compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000008318 pyrimidones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024808.8A GB0024808D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GC0000307A true GC0000307A (en) | 2006-11-01 |
Family
ID=9901006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GCP20011661 GC0000307A (en) | 2000-10-10 | 2001-10-08 | Pyrimidone compounds and pharmaceutical composition containing them |
Country Status (29)
Country | Link |
---|---|
US (2) | US20040063753A1 (en) |
EP (2) | EP2258688B1 (en) |
JP (1) | JP4212354B2 (en) |
KR (1) | KR100824134B1 (en) |
CN (2) | CN1280275C (en) |
AR (1) | AR035349A1 (en) |
AT (1) | ATE538096T1 (en) |
AU (2) | AU2002210524B2 (en) |
BR (1) | BRPI0114576B1 (en) |
CA (1) | CA2425268C (en) |
CY (2) | CY1112442T1 (en) |
CZ (1) | CZ304558B6 (en) |
DK (2) | DK1326841T3 (en) |
ES (2) | ES2399325T3 (en) |
GB (1) | GB0024808D0 (en) |
GC (1) | GC0000307A (en) |
HK (2) | HK1144941A1 (en) |
HU (1) | HU230767B1 (en) |
IL (2) | IL155278A0 (en) |
MX (1) | MXPA03003176A (en) |
MY (1) | MY135766A (en) |
NO (1) | NO325107B1 (en) |
NZ (1) | NZ525225A (en) |
PL (1) | PL207560B1 (en) |
PT (2) | PT1326841E (en) |
SI (2) | SI1326841T1 (en) |
TW (1) | TWI293293B (en) |
WO (1) | WO2002030904A1 (en) |
ZA (1) | ZA200302785B (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60139429D1 (en) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidine-5-onderivatives as LDL-PLA2 inhibitors |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
US20070166777A1 (en) | 2004-04-16 | 2007-07-19 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
EA200971050A1 (en) * | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
CN101687009A (en) * | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | Methods of treatment of skin ulcers |
US8575348B2 (en) | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
US9512104B2 (en) | 2009-07-28 | 2016-12-06 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
EP2490693A4 (en) * | 2009-10-19 | 2013-02-27 | Merck Sharp & Dohme | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS |
US9011821B2 (en) | 2010-06-18 | 2015-04-21 | Whitehead Institute For Biomedical Research | PLA2G16 as a target for antiviral compounds |
TW201307324A (en) * | 2010-12-06 | 2013-02-16 | Glaxo Group Ltd | Compounds |
EP2649050A4 (en) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | Compounds |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
WO2013000108A1 (en) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | Azole heterocylic compounds, preparation methods, pharmaceutical compositions and uses thereof |
TW201321382A (en) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | Compounds |
BR112014001665A2 (en) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors |
CN103906744A (en) | 2011-09-01 | 2014-07-02 | 葛兰素集团有限公司 | Novel crystal form |
WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
EP2948452B1 (en) | 2013-01-25 | 2017-08-09 | GlaxoSmithKline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
CA2899143A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
CN104840963B (en) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | The pharmaceutical composition of the inhibitor containing lipoprotein-associated phospholipase A_2 and application |
JP2018521021A (en) | 2015-06-11 | 2018-08-02 | バジリア・ファルマスーチカ・インターナショナル・アーゲーBasilea Pharmaceutica International Ag | Efflux pump inhibitors and their therapeutic use |
CN112574221B (en) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | Tetracyclic pyrimidinone compounds, preparation method, composition and application thereof |
CN112778331B (en) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof |
CN112510260B (en) * | 2020-11-27 | 2022-11-04 | 珠海市赛纬电子材料股份有限公司 | Electrolyte additive, non-aqueous electrolyte and lithium ion battery |
CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5769527A (en) | 1986-07-17 | 1998-06-23 | Vari-Lite, Inc. | Computer controlled lighting system with distributed control resources |
US5585246A (en) | 1993-02-17 | 1996-12-17 | Biometric Imaging, Inc. | Method for preparing a sample in a scan capillary for immunofluorescent interrogation |
EP0974663A1 (en) | 1993-06-25 | 2000-01-26 | Smithkline Beecham Plc | Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy |
DE69434609T2 (en) | 1993-10-06 | 2006-09-21 | Icos Corp., Bothell | Acethylhydrolase of the platelet activating factor |
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
SK80397A3 (en) | 1994-12-22 | 1998-01-14 | Smithkline Beecham Plc | Substituted azetidin-2-ones, preparation method thereof, farmaceutical compositions and their use |
CH690264A5 (en) | 1995-06-30 | 2000-06-30 | Symphar Sa | aminophosphonates substituted derivatives, their preparation process and their use for preparing pharmaceutical compositions. |
SK178497A3 (en) | 1995-07-01 | 1998-07-08 | Smithkline Beecham Plc | Azetidinone derivatives, method for producing the same, pharmaceutical composition containing same and their use |
FR2743912B1 (en) | 1996-01-24 | 1998-04-10 | Matra Communication | KEY EQUATION RESOLUTION CIRCUIT AND REED-SOLOMON DECODER INCORPORATING SUCH A CIRCUIT |
US5684794A (en) | 1996-01-25 | 1997-11-04 | Hazeltine Corporation | Validation of subscriber signals in a cellular radio network |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
NZ335992A (en) * | 1996-12-05 | 2001-09-28 | Amgen Inc | Substituted pyrimidinone and pyridone compounds and methods of use |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
DE69816471T2 (en) * | 1997-11-06 | 2004-05-27 | Smithkline Beecham P.L.C., Brentford | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2000010980A1 (en) | 1998-08-21 | 2000-03-02 | Smithkline Beecham Plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
IL146210A0 (en) | 1999-05-01 | 2002-07-25 | Smithkline Beecham Plc | Pyrimidinone compounds |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-10-10 GB GBGB0024808.8A patent/GB0024808D0/en not_active Ceased
-
2001
- 2001-10-05 WO PCT/EP2001/011610 patent/WO2002030904A1/en active IP Right Grant
- 2001-10-05 CN CNB018201253A patent/CN1280275C/en not_active Expired - Fee Related
- 2001-10-05 SI SI200131008T patent/SI1326841T1/en unknown
- 2001-10-05 CN CN200610128890XA patent/CN1951917B/en not_active Expired - Fee Related
- 2001-10-05 NZ NZ525225A patent/NZ525225A/en not_active IP Right Cessation
- 2001-10-05 CZ CZ2003-1009A patent/CZ304558B6/en not_active IP Right Cessation
- 2001-10-05 DK DK01978400.8T patent/DK1326841T3/en active
- 2001-10-05 SI SI200131019T patent/SI2258688T1/en unknown
- 2001-10-05 IL IL15527801A patent/IL155278A0/en unknown
- 2001-10-05 CA CA2425268A patent/CA2425268C/en not_active Expired - Fee Related
- 2001-10-05 HU HU0302480A patent/HU230767B1/en not_active IP Right Cessation
- 2001-10-05 DK DK10177773.8T patent/DK2258688T3/en active
- 2001-10-05 PT PT01978400T patent/PT1326841E/en unknown
- 2001-10-05 MX MXPA03003176A patent/MXPA03003176A/en active IP Right Grant
- 2001-10-05 PT PT101777738T patent/PT2258688E/en unknown
- 2001-10-05 EP EP10177773A patent/EP2258688B1/en not_active Expired - Lifetime
- 2001-10-05 AU AU2002210524A patent/AU2002210524B2/en not_active Ceased
- 2001-10-05 US US10/399,022 patent/US20040063753A1/en not_active Abandoned
- 2001-10-05 ES ES10177773T patent/ES2399325T3/en not_active Expired - Lifetime
- 2001-10-05 AU AU1052402A patent/AU1052402A/en active Pending
- 2001-10-05 PL PL366334A patent/PL207560B1/en unknown
- 2001-10-05 KR KR1020037005084A patent/KR100824134B1/en active IP Right Grant
- 2001-10-05 BR BRPI0114576A patent/BRPI0114576B1/en not_active IP Right Cessation
- 2001-10-05 EP EP01978400A patent/EP1326841B1/en not_active Expired - Lifetime
- 2001-10-05 AT AT01978400T patent/ATE538096T1/en active
- 2001-10-05 JP JP2002534290A patent/JP4212354B2/en not_active Expired - Fee Related
- 2001-10-05 ES ES01978400T patent/ES2378059T3/en not_active Expired - Lifetime
- 2001-10-08 MY MYPI20014669A patent/MY135766A/en unknown
- 2001-10-08 TW TW090124779A patent/TWI293293B/en not_active IP Right Cessation
- 2001-10-08 GC GCP20011661 patent/GC0000307A/en active
- 2001-10-10 AR ARP010104760A patent/AR035349A1/en active IP Right Grant
-
2003
- 2003-04-08 IL IL155278A patent/IL155278A/en not_active IP Right Cessation
- 2003-04-09 NO NO20031626A patent/NO325107B1/en not_active IP Right Cessation
- 2003-04-09 ZA ZA200302785A patent/ZA200302785B/en unknown
- 2003-12-08 HK HK10111562.3A patent/HK1144941A1/en not_active IP Right Cessation
- 2003-12-08 HK HK03108904.5A patent/HK1058036A1/en not_active IP Right Cessation
-
2004
- 2004-07-28 US US10/900,489 patent/US7235566B2/en not_active Expired - Lifetime
-
2012
- 2012-03-07 CY CY20121100228T patent/CY1112442T1/en unknown
-
2013
- 2013-02-08 CY CY20131100118T patent/CY1113648T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GC0000307A (en) | Pyrimidone compounds and pharmaceutical composition containing them | |
IL148489A0 (en) | Quinazoline compounds and pharmaceutical compositions containing them | |
HUP0203939A3 (en) | Pharmaceutical compounds and compositions containing them and their use | |
HUP0203378A3 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
HUP0401950A3 (en) | Pyrimidine derivatives and pharmaceutical compositions containing that compounds | |
HUP0301722A3 (en) | Pyrimidine derivatives, pharmaceutical compositions containing them and their use | |
HUP0204514A3 (en) | Pyridinylimidazoles, pharmaceutical compositions containing them and their use | |
IL152451A0 (en) | 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same | |
HUP0301178A3 (en) | Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same | |
IL152659A0 (en) | Pharmaceutical composition | |
HK1075889A1 (en) | Pharmaceutical composition | |
IL153123A0 (en) | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same | |
IL209444A0 (en) | O-desmethyl-venlafaxine succinate salts and pharmaceutical compositions containing them | |
HUP0401333A3 (en) | Spiropyrazole compounds and pharmaceutical compositions containing them | |
HUP0204555A3 (en) | Pharmaceutical composition | |
HUP0400967A3 (en) | Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them | |
HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them | |
HUP0000137A3 (en) | Controller-release pharmaceutical composition containing anangetics | |
HUP0200747A2 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
IL154238A0 (en) | Pharmaceutical composition | |
HUP0302397A3 (en) | Heterocyclic compounds and pharmaceutical compositions containing them | |
HUP0303204A3 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing them | |
HUP0302648A3 (en) | Bicyclic heteroaromatic compounds, pharmaceutical compositions containing them and their use | |
HUP0301582A3 (en) | Calcilytic compounds and pharmaceutical compositions containing them | |
HUP0203383A3 (en) | Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |